J&J exits from DES market as competition gets too heated; takes $600m earning hit with Cordis overhaul
This article was originally published in Clinica
Executive Summary
Johnson & Johnson subsidiary Cordis is planning to halt development of its investigational drug-eluting stent (DES) Nevo, as well as cease production of its already-marketed Cypher and Cypher Select Plus stents by the end of the year. The company will continue to sell its bare metal stents and said it was planning to focus on other cardiovascular therapies "where significant patient need exists".